Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: The national FINRISK study

American Journal of Cardiovascular Drugs

Volumn 6, Issue 5, 2006, Pages 349-355

  Alemao, Evo ^a   Yin, Don ^a   Sintonen, Harri ^b   Salomaa, Veikko ^c   Jousilahti, Pekka ^c,d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; FINLAND; HEALTH BEHAVIOR; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; SECONDARY PREVENTION;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; COHORT STUDIES; CORONARY DISEASE; FEMALE; FINLAND; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES; QUESTIONNAIRES; RISK FACTORS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 33751007239     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606050-00008     Document Type: Article

References (40)

1. European Heart Network. CVD statistics: statistical data about cardiovascular disease in Europe [online]. Available from URL: http://www.ehnheart.org/content/sectionintro.asp?level0 = 1457 [Accessed 2005 Aug 22]
2. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other societies on cardiovascular disease prevention and clinical practice. Eur J Cardiovasc Prev Rehabil 2003 Aug; 10 Suppl. 1: S1-78
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 Jul; 110 (2): 27-39
4. Adult Treatment Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec; 106 (25): 3143-421
5. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001 Mar; 357 (9261): 995-1001
6. Van Ganse E, Souchet T, Laforest L, et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol 2005 Apr; 59 (4): 456-63
7. Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005 Sep; 21 (9): 1389-99
8. Primatesta P, Poulter NR. Lipid levels and the use of lipid-lowering agents in England and Scotland. Eur J Cardiovasc Prev Rehabil 2004 Dec; 11 (6): 484-8
9. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000 Feb; 160 (4): 459-67
10. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999 May; 83 (9): 1303-7
11. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999 Dec; 14 (12): 711-7
12. Campbell NC, Thain J, Deans HG, et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998 May; 316 (7142): 1430-4
13. McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998 Jun; 158 (11): 1238-44
14. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996 Jun; 100 (6): 605-10
15. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996 Feb; 100 (2): 197-204
16. Vartiainen E, Jousilahti P, Alfthan G, et al. Cardiovascular risk factor changes in Finland, 1972-1997. Int J Epidemiol 2000 Feb; 29 (1): 49-56
17. World Health Organization. MONICA manual. Geneva, Switzerland: 1998 [on-line]. Available from URL: http://www.ktl.fi/publications/monica/manual/ part1/i-1.htm [Accessed 2005 Aug 15]
18. World Health Organization. The World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988; 41 (2): 105-14
19. Vartiainen E, Puska P, Pekkanen J, et al. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994 Jul; 309 (6946): 23-7
20. de Jong N, Simojoki M, Laatikainen T, et al. The combined use of cholesterol-lowering drugs and cholesterol-lowering bread spreads: health behavior data from Finland. Prev Med 2004 Nov; 39 (5): 849-55
21. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999 Mar; 99 (9): 1165-72
22. Puska P, Tuomilehto J, Nissinen A, et al. The North Karelia Project: 20 year results and experiences. Helsinki: National Public Health Institute (KTL), 1995
23. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000 Jan; 101 (2): 207-13
24. National Guideline Clearinghouse. Agency for Healthcare Research and Quality, US Department of Health and Human Services [online]. Available from URL: http://www.guidelines.gov [Accessed 2006 Oct 30]
25. Wood D, De Backer G, Færgeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998 Oct; 19 (10): 1434-503
26. British Cardiac Society, British Hypertension Society, Diabetes UK. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 Suppl. 5: v1-52
27. Jousilahti P, Vartiainen E, Pekkanen J, et al. Serum cholesterol distribution and coronary heart disease risk: observations and predictions among middle-aged population in eastern Finland. Circulation 1998 Mar; 97 (11): 1087-94
28. Nissinen A, Tuomilehto J, Puska P. From pilot project to national implementation: experiences from the North Karelia Project. Scand J Prim Health Care Suppl 1988; 1: 49-56
29. Davidson MH, Maki KC, Karp SK, et al. Management of hypercholesterolaemia in postmenopausal women. Drugs Aging 2002; 19 (3): 169-78
30. Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998 Aug; 280 (7): 605-13
31. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative; a randomized trial. JAMA 2003 May; 289 (20): 2673-84
32. Rossouw JE, Anderson GL, Prentice RL, et al., for the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 Jul; 288 (3): 321-33
33. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative randomized controlled dietary modification trial. JAMA 2006 Feb; 295 (6): 655-66
34. Insull Jr W, Davidson MH, Kulkarni PM, et al. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism 2005 Jul; 54 (7): 939-46
35. Shepherd J, Packard C, Littlejohn III TW, et al. Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy. Curr Med Res Opin 2004; 20 (10): 1571-8
36. Ushiroyama T, Ikeda A, Ueki M. Beneficial effects of pravastatin in peri- and postmenopausal hyperlipidemic women: a 5-year study on serum lipid and sex hormone levels. Maturitas 2001 Jan; 37 (3): 201-8
37. Sbarouni E, Flevari P, Kroupis C, et al. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drugs Ther 2003 Jul; 17 (4): 319-23
38. Clearfield M. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women. Curr Atheroscler Rep 2006 Jan; 8 (1): 10-2
39. Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation 2005 Jul; 112 (4): 563-71
40. Jousilahti P, Salomaa V, Kuulasmaa K, et al. Total and cause specific mortality among participants and non-participants of population based health surveys: a comprehensive follow up of 54 372 Finnish men and women. J Epidemiol Community Health 2005 Apr; 59 (4): 310-5